Figure 4From: A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors Effect of KRAS knockdown on viability of cells harboring a KRAS mutation. (A) KRAS mutant or (B) KRAS wild-type cells were selected for KRAS knockdown. Scatterplots indicate that these lines show variable sensitivity to MEK inhibition. The Y-axis shows RAS siganture score, and the X-axis show cell sensitivity to MEK inhibition. Lower numbers on the X-axis indicate increasing sensitivity. Cell lines in red text were treated with siRNAs targeting KRAS. Western blots were performed for KRAS and B-actin. Control = Dharmacon non-targeting siRNA pool; KRAS = siRNA targeting KRAS, none = no transfection. Bar charts show viability as measured by the ATP vialight assay. The percent viability relative to the control siRNA is shown. R = Pearson correlation coefficient, p = the corresponding P-value.Back to article page